Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announces its participation in the Piper Sandler 36th Annual Healthcare Conference. Chairman and CEO David Fischel will present the company's technology and growth strategy on December 5, 2024, at 2:00 pm ET, and will be available for one-on-one meetings.
The company's innovative robotics technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions. Stereotaxis focuses on developing robotic systems, instruments, and information solutions for the interventional laboratory, aiming to enhance physician care delivery with robotic precision and safety.
Stereotaxis (NYSE: STXS), leader nella robotica chirurgica per interventi endovascolari minimamente invasivi, annuncia la sua partecipazione alla 36° Conferenza Annuale sulla Salute di Piper Sandler. Il Presidente e CEO David Fischel presenterà la tecnologia e la strategia di crescita dell'azienda il 5 dicembre 2024, alle 14:00 ET, e sarà disponibile per incontri one-to-one.
La tecnologia innovativa della robotica dell'azienda è stata utilizzata nel trattamento di oltre 150.000 pazienti a livello globale, negli Stati Uniti, in Europa, Asia e in altre regioni. Stereotaxis si concentra nello sviluppo di sistemi robotici, strumenti e soluzioni informative per il laboratorio interventistico, con l'obiettivo di migliorare l'assistenza ai medici con precisione e sicurezza robotiche.
Stereotaxis (NYSE: STXS), líder en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, anuncia su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El presidente y CEO David Fischel presentará la tecnología y la estrategia de crecimiento de la empresa el 5 de diciembre de 2024, a las 2:00 p.m. ET, y estará disponible para reuniones uno a uno.
La innovadora tecnología robótica de la empresa ha sido utilizada para tratar a más de 150,000 pacientes en todo el mundo, incluyendo Estados Unidos, Europa, Asia y otras regiones. Stereotaxis se enfoca en desarrollar sistemas robóticos, instrumentos y soluciones de información para el laboratorio intervencionista, con el objetivo de mejorar la atención al paciente por parte de los médicos con precisión y seguridad robótica.
스테레오택시스 (NYSE: STXS)는 최소 침습 혈관 내 시술을 위한 외과 로봇 분야의 선두주자로서 파이퍼 샌들러 제36회 연례 의료 컨퍼런스에 참여한다고 발표했습니다. 의장 겸 CEO인 데이비드 피셔엘은 2024년 12월 5일 오후 2시 ET에 회사의 기술 및 성장 전략을 발표하고 일대일 미팅을 위해 대기할 것입니다.
회사의 혁신적인 로봇 기술은 미국, 유럽, 아시아 및 기타 지역에서 전 세계적으로 15만 명 이상의 환자를 치료하는 데 활용되었습니다. 스테레오택시스는 중재실을 위한 로봇 시스템, 기기 및 정보 솔루션 개발에 초점을 맞추고 있으며, 로봇의 정확성과 안전성으로 의사의 치료 제공을 향상시키는 것을 목표로 합니다.
Stereotaxis (NYSE: STXS), un leader dans la robotique chirurgicale pour les interventions endovasculaires peu invasives, annonce sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. Le Président et CEO, David Fischel, présentera la technologie et la stratégie de croissance de l'entreprise le 5 décembre 2024, à 14h00 ET, et sera disponible pour des rencontres individuelles.
La technologie robotique innovante de l'entreprise a été utilisée pour traiter plus de 150 000 patients à l'échelle mondiale, aux États-Unis, en Europe, en Asie et dans d'autres régions. Stereotaxis se concentre sur le développement de systèmes robotiques, d'instruments et de solutions d'information pour le laboratoire d'intervention, avec pour objectif d'améliorer la qualité des soins fournis par les médecins grâce à la précision et à la sécurité robotisées.
Stereotaxis (NYSE: STXS), ein führendes Unternehmen in der chirurgischen Robotik für minimal-invasive endovaskuläre Eingriffe, gibt seine Teilnahme an der 36. Jahrestagung des Piper Sandler Healthcare Conference bekannt. Vorsitzender und CEO David Fischel wird am 5. Dezember 2024 um 14:00 Uhr ET die Technologie und Wachstumsstrategie des Unternehmens präsentieren und ist für persönliche Gespräche verfügbar.
Die innovative Robotertechnologie des Unternehmens wurde weltweit zur Behandlung von über 150.000 Patienten in den Vereinigten Staaten, Europa, Asien und anderen Regionen eingesetzt. Stereotaxis konzentriert sich auf die Entwicklung von Robotersystemen, Instrumenten und Informationslösungen für das interventionelle Labor, mit dem Ziel, die Patientenversorgung durch robotergenauigkeit und -sicherheit zu verbessern.
- None.
- None.
ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 36th Annual Healthcare Conference.
Mr. Fischel will deliver a formal presentation on Stereotaxis’ technology and growth strategy on Thursday, December 5, 2024, at 2:00 pm ET. Mr. Fischel will be available for one-on-one meetings that same day.
“This is an exciting period for Stereotaxis and we look forward to sharing our progress in realizing an attractive growth strategy,” said Mr. Fischel. “We appreciate the opportunity to engage with investors at the Piper Sandler conference.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When is Stereotaxis (STXS) presenting at the Piper Sandler Healthcare Conference?
How many patients have been treated using Stereotaxis (STXS) technology?
What will be discussed at Stereotaxis (STXS) Piper Sandler conference presentation?
What type of medical technology does Stereotaxis (STXS) develop?
